Eloxx Pharmaceuticals Inc. Stock News

Analysts expect that Senesco Technologies Inc. (NYSE:ELOX) will post earnings of ($0.36) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Senesco Techno

H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Eloxx Pharmaceuticals (ELOX) today and set a price target of $3.00. The company's shares

H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Eloxx Pharmaceuticals ( ELOX – Research Report ) today and set a price target of $3.00 . The company’s shares closed last Monday at

ELOX earnings call for the period ending December 31, 2019.

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Q4 2019 Earnings Conference Call March 05, 2020 4:30 PM ET Company Participants Barbara Ryan - Investor Relations Greg

Topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 in H1 2020 Realignment strengthens commitment to Cystic Fibrosis and strategic flexibility by extending.

NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Eloxx Pharmaceuticals, Inc. (ELOX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In

Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 45% to close at $3.03 on Wednesday. Cellect Biotechnology and Canndoc Ltd. agreed to enter into strategic pharma...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLa

Senesco Technologies Inc. (NYSE:ELOX) has been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One equi

Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by no

Thinly traded micro cap Eloxx Pharmaceuticals (ELOX -29.6%) slumps on 82% higher volume, a modest 527K shares, on the heels of its update on lead drug ELX-02, a eukaryotic ribosomal selective glycosid

Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of...